 Proto-Oncogene Proteins B-raf
"Proto-Oncogene Proteins B-raf" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A raf kinase subclass found at high levels in neuronal tissue. The B-raf Kinases are MAP kinase kinase kinases that have specificity for MAP KINASE KINASE 1 and MAP KINASE KINASE 2.
| Descriptor ID |
D048493
|
| MeSH Number(s) |
D08.811.913.696.620.682.700.559.842.374 D12.644.360.400.842.374 D12.776.476.400.842.437 D12.776.624.664.700.204.200
|
| Concept/Terms |
Proto-Oncogene Proteins B-raf- Proto-Oncogene Proteins B-raf
- B-raf, Proto-Oncogene Proteins
- Proteins B-raf, Proto-Oncogene
- Proto Oncogene Proteins B raf
- BRAF Kinases
- B-raf Kinases
- B raf Kinases
- Proto-Oncogene Protein B-raf
- B-raf, Proto-Oncogene Protein
- Protein B-raf, Proto-Oncogene
- Proto Oncogene Protein B raf
|
Below are MeSH descriptors whose meaning is more general than "Proto-Oncogene Proteins B-raf".
Below are MeSH descriptors whose meaning is more specific than "Proto-Oncogene Proteins B-raf".
This graph shows the total number of publications written about "Proto-Oncogene Proteins B-raf" by people in this website by year, and whether "Proto-Oncogene Proteins B-raf" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2006 | 1 | 1 | 2 | | 2007 | 0 | 1 | 1 | | 2008 | 2 | 1 | 3 | | 2009 | 3 | 0 | 3 | | 2010 | 0 | 1 | 1 | | 2011 | 1 | 2 | 3 | | 2012 | 3 | 1 | 4 | | 2013 | 3 | 5 | 8 | | 2014 | 7 | 5 | 12 | | 2015 | 6 | 3 | 9 | | 2016 | 2 | 3 | 5 | | 2017 | 9 | 3 | 12 | | 2018 | 3 | 4 | 7 | | 2019 | 4 | 4 | 8 | | 2020 | 2 | 4 | 6 | | 2021 | 5 | 1 | 6 | | 2022 | 1 | 1 | 2 | | 2023 | 2 | 1 | 3 |
To return to the timeline, click here.
Below are the most recent publications written about "Proto-Oncogene Proteins B-raf" by people in Profiles.
-
Romano G, Paradiso F, Li P, Shukla P, Barger LN, El Naggar O, Miller JP, Liang RJ, Helms TL, Lazar AJ, Wargo JA, Taraballi F, Costello JC, Kwong LN. Microparticle-Delivered Cxcl9 Prolongs Braf Inhibitor Efficacy in Melanoma. Cancer Immunol Res. 2023 05 03; 11(5):558-569.
-
Chen JY, Hug C, Reyes J, Tian C, Gerosa L, Fr?hlich F, Ponsioen B, Snippert HJG, Spencer SL, Jambhekar A, Sorger PK, Lahav G. Multi-range ERK responses shape the proliferative trajectory of single cells following oncogene induction. Cell Rep. 2023 03 28; 42(3):112252.
-
Chan PP, Sabus A, Hemenway MS, Chatfield KC, White CJ, Mirsky DM, Foreman NK, Dahl NA. Thromboembolic toxicity observed with concurrent trametinib and lenalidomide therapy. Pediatr Blood Cancer. 2023 03; 70(3):e30190.
-
Lehrer EJ, Gurewitz J, Bernstein K, Kondziolka D, Fakhoury KR, Rusthoven CG, Niranjan A, Wei Z, Lunsford LD, Malouff TD, Ruiz-Garcia H, Peterson JL, Bonney P, Hwang L, Yu C, Zada G, Deibert CP, Prasad RN, Raval RR, Palmer JD, Patel S, Picozzi P, Franzini A, Attuati L, Mathieu D, Trudel C, Lee CC, Yang HC, Jones BM, Green S, Ahluwalia MS, Sheehan JP, Trifiletti DM. Concurrent Administration of Immune Checkpoint Inhibitors and Stereotactic Radiosurgery Is Well-Tolerated in Patients With Melanoma Brain Metastases: An International Multicenter Study of 203 Patients. Neurosurgery. 2022 Dec 01; 91(6):872-882.
-
Hong ES, Messersmith WA, Hammad H, Cornish TC, Aisner DL. Tissue Displacement Versus Two Primary Colorectal Carcinomas? A Case Report on the Utility of Comparative Sequencing. JCO Precis Oncol. 2022 10; 6:e2200252.
-
Moschos SJ, Sandhu S, Lewis KD, Sullivan RJ, Puzanov I, Johnson DB, Henary HA, Wong H, Upreti VV, Long GV, Flaherty KT. Targeting wild-type TP53 using AMG 232 in combination with MAPK inhibition in Metastatic Melanoma; a phase 1 study. Invest New Drugs. 2022 10; 40(5):1051-1065.
-
Kavran AJ, Stuart SA, Hayashi KR, Basken JM, Brandhuber BJ, Ahn NG. Intermittent treatment of BRAFV600E melanoma cells delays resistance by adaptive resensitization to drug rechallenge. Proc Natl Acad Sci U S A. 2022 03 22; 119(12):e2113535119.
-
Robert C, Lewis KD, Gutzmer R, Stroyakovskiy D, Gogas H, Protsenko S, Pereira RP, Eigentler T, Rutkowski P, Demidov L, Caro I, Forbes H, Shah K, Yan Y, Li H, McArthur GA, Ascierto PA. Biomarkers of treatment benefit with atezolizumab plus vemurafenib plus cobimetinib in BRAFV600 mutation-positive melanoma. Ann Oncol. 2022 05; 33(5):544-555.
-
Shin DS, Schroeder ME, Anseth KS. Impact of Collagen Triple Helix Structure on Melanoma Cell Invadopodia Formation and Matrix Degradation upon BRAF Inhibitor Treatment. Adv Healthc Mater. 2022 04; 11(7):e2101592.
-
Molteni R, Biavasco R, Stefanoni D, Nemkov T, Dom?nguez-Andr?s J, Arts RJ, Merelli I, Mazza D, Zambrano S, Panigada M, Cantoni E, Tengesdal IW, Maksud P, Piras F, Cesana D, Cassina L, Distefano G, Loffreda A, Gnani D, De Luca G, Tomelleri A, Campochiaro C, Joosten LAB, Dinarello CA, Kajaste-Rudnitski A, Haroche J, Cardaci S, Cenci S, Dagna L, Doglioni C, Ferrarini M, Ferrero E, Boletta A, D'Alessandro A, Montini E, Netea MG, Cavalli G. Oncogene-induced maladaptive activation of trained immunity in the pathogenesis and treatment of Erdheim-Chester disease. Blood. 2021 10 28; 138(17):1554-1569.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|